Steven Gabardi1,2,3, Spencer Martin4, Mihir Sura5, Anisa Mohammed4, Yoav Golan5. 1. Departments of Transplant Surgery and Pharmacy Services, and the Renal Division, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02115, USA. sgabardi@partners.org. 2. Department of Medicine, Harvard Medical School, 25 Shattuck Street, Boston, MA, 02115, USA. sgabardi@partners.org. 3. Department of Pharmacy Service, Brigham and Women's Hospital, Boston, MA, 02115, USA. sgabardi@partners.org. 4. Department of Pharmacy Service, Brigham and Women's Hospital, Boston, MA, 02115, USA. 5. Division of Infectious Diseases, Tufts Medical Center, Boston, MA, USA.
Abstract
PURPOSE: In high-risk patients, candiduria may be associated with the development of urinary tract infections (UTI) and invasive candidiasis. The triazole antifungals achieve good urine concentrations, but their use is limited by the emergence of non-albicans Candida spp. with low-triazole susceptibility. The echinocandins remain fungicidal against many azole-resistant Candida spp., but low urine concentrations limit their use. We examined the rates of candiduria elimination in micafungin-treated patients. METHODS: This retrospective analysis evaluated consecutive patients with candiduria (1/2008-4/2011) who were treated with micafungin (100 mg/day) and had post-micafungin urine cultures. Patients were deemed to have either candiduria or UTI and were assessed for short-term (within 2 weeks post-micafungin) and long-term (>1 month post-micafungin) urine sterilization. RESULTS: Thirty-three patients meeting our inclusion criteria were identified. Of these, 16 (48 %) were diagnosed with a Candida UTI. A total of 25 patients (76 %) had Foley catheters, which were replaced in 11 (44 %) cases. The majority of patients had Candida albicans (39 %), but Candida krusei and Candida glabrata (33 %) were also isolated. Eight patients (24 %) were immunocompromised, and 29 (88 %) received broad-spectrum antibiotics. Rates of urine sterilization during micafungin treatment, 2 weeks after micafungin, and >1 month after micafungin were 81, 78, and 75 %, respectively. CONCLUSIONS: Among hospitalized patients with candiduria, micafungin administration was frequently associated with both short- and long-term urine sterilization. This was observed among patients with or without Foley removal and among those with Candida albicans, as well as non-albicans Candida spp.
PURPOSE: In high-risk patients, candiduria may be associated with the development of urinary tract infections (UTI) and invasive candidiasis. The triazole antifungals achieve good urine concentrations, but their use is limited by the emergence of non-albicans Candida spp. with low-triazole susceptibility. The echinocandins remain fungicidal against many azole-resistant Candida spp., but low urine concentrations limit their use. We examined the rates of candiduria elimination in micafungin-treated patients. METHODS: This retrospective analysis evaluated consecutive patients with candiduria (1/2008-4/2011) who were treated with micafungin (100 mg/day) and had post-micafungin urine cultures. Patients were deemed to have either candiduria or UTI and were assessed for short-term (within 2 weeks post-micafungin) and long-term (>1 month post-micafungin) urine sterilization. RESULTS: Thirty-three patients meeting our inclusion criteria were identified. Of these, 16 (48 %) were diagnosed with a Candida UTI. A total of 25 patients (76 %) had Foley catheters, which were replaced in 11 (44 %) cases. The majority of patients had Candida albicans (39 %), but Candida krusei and Candida glabrata (33 %) were also isolated. Eight patients (24 %) were immunocompromised, and 29 (88 %) received broad-spectrum antibiotics. Rates of urine sterilization during micafungin treatment, 2 weeks after micafungin, and >1 month after micafungin were 81, 78, and 75 %, respectively. CONCLUSIONS: Among hospitalized patients with candiduria, micafungin administration was frequently associated with both short- and long-term urine sterilization. This was observed among patients with or without Foley removal and among those with Candida albicans, as well as non-albicans Candida spp.
Authors: Carolyn V Gould; Craig A Umscheid; Rajender K Agarwal; Gretchen Kuntz; David A Pegues Journal: Infect Control Hosp Epidemiol Date: 2010-04 Impact factor: 3.254
Authors: A H Groll; D Mickiene; V Petraitis; R Petraitiene; K H Ibrahim; S C Piscitelli; I Bekersky; T J Walsh Journal: Antimicrob Agents Chemother Date: 2001-12 Impact factor: 5.191
Authors: Laila Rkieh; Wasim S El Nekidy; Leen Oyoun Alsoud; Adnan Alatoom; Rania El Lababidi; Mohamad Mooty; Ahmad R Nusair Journal: IDCases Date: 2022-05-18
Authors: Roeland E Wasmann; Eline W Muilwijk; David M Burger; Paul E Verweij; Catherijne A Knibbe; Roger J Brüggemann Journal: Clin Pharmacokinet Date: 2018-03 Impact factor: 6.447
Authors: Daniel K Benjamin; David A Kaufman; William W Hope; P Brian Smith; Antonio Arrieta; Paolo Manzoni; Laura L Kovanda; Christopher Lademacher; Brigit Isaacson; Deborah Jednachowski; Chunzhang Wu; Atsunori Kaibara; Thomas J Walsh Journal: Pediatr Infect Dis J Date: 2018-10 Impact factor: 2.129